房颤患者严重出血后重启抗凝的时机
早期重启组卒中风险较低但置信区间包含无效值(HR 0.89;95%CI 0.74-1.08),复发性出血风险较高(HR 1.21;95%CI 1.07-1.36);时变分析中DOAC单药治疗较无治疗降低卒中风险(HR 0.78;95%CI 0.68-0.89)但增加出血风险(HR 1.26;95%CI 1.15-1.38)。
要点
- 严重出血后60天内重启DOAC与复发性出血风险升高相关(HR 1.21;95%CI 1.07-1.36)。
- 早期重启对卒中的降低不确定,置信区间包含无效值(HR 0.89;95%CI 0.74-1.08)。
- DOAC单药治疗卒中保护最佳但出血风险亦升高(HR 0.78与1.26)。
核心结论
- 房颤患者严重出血后早期重启DOAC可能降低卒中风险但增加复发性出血风险。
- DOAC单药治疗似乎提供最佳卒中保护,但出血风险升高。
- 需个体化决策并进一步试验确定DOAC重启的最佳时机。
研究设计与样本
- 基于丹麦全国登记(2012-2021)的队列研究。
- 按重启DOAC时间分组:≤60天为早期重启组(5970例),>60天为晚期重启组(4321例)。
- 采用多变量Cox模型估计卒中、复发性出血及复合终点(卒中或严重出血)的风险比。
- 二次分析评估六种时变抗血栓治疗方案的结局。
主要发现
- 早期重启组卒中风险较低但置信区间包含无效值(HR 0.89;95%CI 0.74-1.08)。
- 早期重启组复发性出血更频繁(HR 1.21;95%CI 1.07-1.36)。
- 时变分析中DOAC单药治疗较无治疗降低卒中风险(HR 0.78;95%CI 0.68-0.89)。
- 时变分析中DOAC单药治疗期间出血风险亦较高(HR 1.26;95%CI 1.15-1.38)。
关键数值与推荐
- 早期重启定义为严重出血后60天内重启DOAC。
- 晚期重启定义为严重出血后60天后重启DOAC。
- 纳入标准为CHA₂DS₂-VASc评分≥2的房颤患者。
临床怎么用
- 严重出血后重启DOAC需权衡卒中预防与复发性出血风险。
- DOAC单药治疗可提供最佳卒中保护但需警惕出血风险升高。
- 重启时机应个体化决策,等待进一步试验明确最佳时机。
局限性
- 观察性设计可能存在残余混杂。
- 早期重启组卒中风险降低的置信区间包含无效值,不确定性较大。
- 需进一步随机试验确定最佳重启时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Restarting direct oral anticoagulants (DOACs) after a serious bleeding event in patients with atrial fibrillation (AF) presents a clinical dilemma, with limited evidence on the balance between stroke prevention and recurrent bleeding risk. METHODS: Using nationwide Danish registries (2012-2021), we identified AF patients (Congestive heart failure, Hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65-74, and Sex category (female) (CHA₂DS₂-VASc score ≥2)) who experienced a first serious bleeding event while on DOAC therapy. Patients were grouped by timing of DOAC restart: within 60 days ('early restarters') vs after 60 days ('late restarters'). HRs for stroke, recurrent bleeding and a composite endpoint (stroke or serious bleeding) were estimated using multivariable Cox models. A secondary analysis examined outcomes across six time-varying antithrombotic treatment regimens. RESULTS: Among 10 291 patients who survived 60 days postbleeding, 5970 restarted DOAC early and 4321 later. The early restart group had a lower rate of stroke (HR 0.89; 95% CI 0.74 to 1.08), but the interval includes both moderate benefit and no clear difference, indicating uncertainty in the stroke reduction. Recurrent bleeding was more frequent in early restarters (HR 1.21; 95% CI 1.07 to 1.36). In the time-varying analysis, DOAC monotherapy was associated with reduced stroke risk compared with no treatment (HR 0.78; 95% CI 0.68 to 0.89). However, bleeding risk was also higher during DOAC monotherapy (HR 1.26; 95% CI 1.15 to 1.38). CONCLUSIONS: Restarting DOACs early after a serious bleeding event in AF patients may reduce stroke risk but is associated with an increased risk of recurrent bleeding. DOAC monotherapy appears to offer the best stroke protection, though with elevated bleeding risk. These findings highlight the need for individualised decision-making and further trials to define optimal timing for DOAC resumption.
引用
- Al-Hussainy, Kragholm, Lundbye-Christensen, et al. Timing of anticoagulation restart after serious bleeding in atrial fibrillation. Heart. 2026. PMID: 40670148. doi:10.1136/heartjnl-2024-325343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。